![Andrew Stamford](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew Stamford
Private Equity Investor chez Deerfield Management Co. LP (Private Equity)
Postes actifs de Andrew Stamford
Sociétés | Poste | Début | Fin |
---|---|---|---|
Deerfield Management Co. LP (Private Equity)
![]() Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York. | Private Equity Investor | 01/05/2020 | - |
Historique de carrière de Andrew Stamford
Anciens postes connus de Andrew Stamford
Sociétés | Poste | Début | Fin |
---|---|---|---|
Bridge Medicines LLC
![]() Bridge Medicines LLC Pharmaceuticals: MajorHealth Technology Bridge Medicines LLC operates as a drug discovery company. It provides spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases. The company was founded on November 1, 2016 and is headquartered in New York, NY. | Private Equity Investor | 01/02/2017 | 01/05/2020 |
Tri-Institutional Therapeutics Discovery Institute, Inc.
![]() Tri-Institutional Therapeutics Discovery Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg. | Private Equity Investor | 01/02/2017 | 01/08/2018 |
Formation de Andrew Stamford
University of Tasmania | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 4 |
Australie | 2 |
Opérationnelle
Private Equity Investor | 3 |
Undergraduate Degree | 1 |
Sectorielle
Finance | 2 |
Health Technology | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
Deerfield Management Co. LP (Private Equity)
![]() Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York. | Finance |
Bridge Medicines LLC
![]() Bridge Medicines LLC Pharmaceuticals: MajorHealth Technology Bridge Medicines LLC operates as a drug discovery company. It provides spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases. The company was founded on November 1, 2016 and is headquartered in New York, NY. | Health Technology |
Tri-Institutional Therapeutics Discovery Institute, Inc.
![]() Tri-Institutional Therapeutics Discovery Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg. | Commercial Services |
- Bourse
- Insiders
- Andrew Stamford
- Expérience